

ZIOPHARM ONCOLOGY INC  
 Form 3  
 June 12, 2013

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
 Expires: January 31, 2005  
 Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

|  |  |   |  |  |
|--|--|---|--|--|
| 1. Name and Address of Reporting Person *<br>Lafond Kevin G<br>(Last) (First) (Middle) | 2. Date of Event Requiring Statement<br>(Month/Day/Year)<br>06/03/2013 | 3. Issuer Name and Ticker or Trading Symbol<br>ZIOPHARM ONCOLOGY INC [ZIOP] | 4. Relationship of Reporting Person(s) to Issuer<br><br>(Check all applicable)<br><br><input type="checkbox"/> Director <input type="checkbox"/> 10% Owner<br><input checked="" type="checkbox"/> Officer <input type="checkbox"/> Other<br>(give title below) (specify below)<br>Vice Pres., Treasurer, & CAO | 5. If Amendment, Date Original Filed(Month/Day/Year) |
|--|--|---|--|--|

C/O ZIOPHARM ONCOLOGY, INC., 1 FIRST AVE. PARRIS BLDG. #34, NAVY YARD  
 (Street)

BOSTON, MA 02129  
 (City) (State) (Zip)

6. Individual or Joint/Group Filing(Check Applicable Line)  
 Form filed by One Reporting Person  
 Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

| 1. Title of Security<br>(Instr. 4) | 2. Amount of Securities Beneficially Owned<br>(Instr. 4) | 3. Ownership Form:<br>Direct (D)<br>or Indirect (I)<br>(Instr. 5) | 4. Nature of Indirect Beneficial Ownership<br>(Instr. 5) |
|------------------------------------|--|---|--|
| Common Stock                       | 36,046 <sup>(1)</sup>                                    | D   |  |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

| 1. Title of Derivative Security<br>(Instr. 4) | 2. Date Exercisable and Expiration Date<br>(Month/Day/Year) | 3. Title and Amount of Securities Underlying Derivative Security<br>(Instr. 4) | 4. Conversion or Exercise Price of Derivative | 5. Ownership Form of Derivative Security: | 6. Nature of Indirect Beneficial Ownership<br>(Instr. 5) |
|---|---|--|---|---|--|
|---|---|--|---|---|--|

Edgar Filing: ZIOPHARM ONCOLOGY INC - Form 3

|                                      | Date Exercisable | Expiration Date | Title        | Amount or Number of Shares | Security | Direct (D) or Indirect (I) (Instr. 5) |   |
|--------------------------------------|------------------|-----------------|--------------|----------------------------|----------|---------------------------------------|---|
| Employee Stock Option (Right to Buy) | Â (2)            | 02/06/2019      | Common Stock | 3,334                      | \$ 0.8   | D                                     | Â |
| Employee Stock Option (Right to Buy) | Â (2)            | 12/31/2019      | Common Stock | 11,667                     | \$ 2.85  | D                                     | Â |
| Employee Stock Option (Right to Buy) | Â (3)            | 12/31/2020      | Common Stock | 25,000                     | \$ 4.77  | D                                     | Â |
| Employee Stock Option (Right to Buy) | Â (4)            | 12/31/2022      | Common Stock | 20,000                     | \$ 4.16  | D                                     | Â |

## Reporting Owners

| Reporting Owner Name / Address  | Relationships |           |                                |       |
|---|---------------|-----------|--------------------------------|-------|
|   | Director      | 10% Owner | Officer                        | Other |
| Lafond Kevin G<br>C/O ZIOPHARM ONCOLOGY, INC.<br>1 FIRST AVE. PARRIS BLDG. #34, NAVY YARD<br>BOSTON, MA 02129 | Â             | Â         | Â Vice Pres., Treasurer, & CAO | Â     |

## Signatures

/s/ Kevin G. 06/12/2012  
Lafond

\_\_Signature of Reporting Person Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes 9,380 shares of restricted stock, of which 4,690 shares vest on each of 12/30/13 and 12/30/14.
- (2) Fully vested.
- (3) The option is vested with respect to 16,667 shares; the option vests with respect to the remaining 8,333 shares on 12/31/2013.
- (4) The option vests in three equal installments on 12/31/2013, 12/31/2014 and 12/31/2015.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.